Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ: RAPT )

1.171 +0.031 (+2.72%)
Streaming Delayed Price Updated: 10:27 AM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
RAPT Stock: The Big Study News That Has RAPT Therapeutics Rocketing 100%+
RAPT Therapeutics (RAPT) stock is rocketing higher on Monday thanks to positive results from a recent clinical trial of RPT193. 
Via InvestorPlace
Mid-Day Market Update: Nasdaq Rises Over 50 Points; Washington Prime Group Shares Plunge
Midway through trading Monday, the Dow traded down 0.65% to 34,255.66 while the NASDAQ rose 0.41% to 14,126.79. The S&P also fell, dropping 0.23% to 4,237.53. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
40 Stocks Moving In Monday's Mid-Day Session
Gainers Enochian Biosciences, Inc. (NASDAQ: ENOB) shares jumped 127.2% to $10.02. The FDA has accepted Enochian BioSciences Inc's pre-IND (Investigational New Drug) request... 
Via Benzinga
Exposures Product Safety
Mid-Morning Market Update: Markets Mostly Lower; Accenture To Acquire German Engineering Company
Following the market opening Monday, the Dow traded down 0.43% to 34,332.41 while the NASDAQ rose 0.24% to 14,102.61. The S&P also fell, dropping 0.20% to 4,238.80. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study
RAPT Therapeutics Inc (NASDAQ: RAPT) has announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).... 
Via Benzinga
48 Biggest Movers From Friday
Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.